COMPANY

Arbutus Biopharma

HQ: Warminster, PA source · arbutusbio.com ↗

Arbutus Biopharma is a clinical-stage biopharmaceutical company with virology expertise. Arbutus Biopharma develops combination drugs that attack HBV through multiple mechanisms of action. From company website Source · checked 2026-10-19

Arbutus Biopharma is listed on ClinicalTrials.gov as the lead sponsor of 11 studies; the most recently updated is “Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection” (Phase 2, completed), in Chronic Hepatitis b. From public records Source · 2026-10-12

Sources for this description (2)

Arbutus Biopharma is a clinical-stage biopharmaceutical company with virology expertise.
- “We are a clinical-stage biopharmaceutical company with deep virology expertise and an unwavering focus on curing conditions with unmet medical need.” https://www.arbutusbio.com/about-arbutus/ (2026-10-19)
Arbutus Biopharma develops combination drugs that attack HBV through multiple mechanisms of action.
- “We are focused on the development of combination drugs to attack HBV through multiple mechanisms of action to significantly improve treatment options and outcomes for patients.” https://www.arbutusbio.com/about-arbutus/ (2026-10-19)

Keywords: Ebola Virus Infection Long Term Follow-up Hepatocellular Carcinoma Hepatoma Adult Liver Cancer Adult Liver Cell Carcinoma Neuroendocrine Tumors Adrenocortical Carcinoma Hypercholesterolemia AB-836 TKM-080301 AB-729 AB-101 ARB-001467 TKM-100802 TKM-100201 PRO-040201

Location: Warminster, PA · source · Aug 21, 2026

Profile checked Oct 10, 2026

11Trials (company is sponsor)

Timeline

Jul 11, 2024 Trial start —: Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729) source ↗
May 1, 2024 Trial start Phase 2: Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV Infection source ↗
Aug 30, 2023 Trial start Phase 1: Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects. source ↗
Oct 29, 2021 Trial start Phase 2: Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection source ↗
Jun 25, 2021 Trial start Phase 1: Safety, Tolerability, and Pharmacokinetics of AB-836 in Healthy Subjects and Subjects With Chronic HBV Infection source ↗
2015-12 Trial start Phase 2: Study of ARB-001467 in Subjects With Chronic HBV Infection Receiving Nucleos(t)Ide Analogue Therapy source ↗
2014-06 Trial start Phase 1/Phase 2: Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma source ↗
2014-01 Trial start Phase 1: Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study for Intravenous (IV) TKM-100802 source ↗
2012-01 Trial start Phase 1: Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study of Intravenous (IV) TKM-100201 Infusion source ↗
2010-12 Trial start Phase 1/Phase 2: A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients source ↗
2009-06 Trial start Phase 1: Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Liposomal siRNA in Subjects With High Cholesterol source ↗

Upcoming milestones

Aug 30, 2029 (ESTIMATED) · · Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729) · NCT06277037

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 11

Record	Title	Phase	Status	Start	Primary completion
NCT04980482	Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection	Phase 2	Completed	Oct 29, 2021	Mar 13, 2025 (actual)
NCT05960240	Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects.	Phase 1	Completed	Aug 30, 2023	Dec 4, 2025 (actual)
NCT06277037	Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729)	Not listed	Recruiting	Jul 11, 2024	Aug 30, 2029 (estimated)
NCT06245291	Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV Infection	Phase 2	Withdrawn	May 1, 2024	Aug 1, 2024 (actual)
NCT04775797	Safety, Tolerability, and Pharmacokinetics of AB-836 in Healthy Subjects and Subjects With Chronic HBV Infection	Phase 1	Terminated	Jun 25, 2021	Nov 17, 2022 (actual)
NCT02191878	Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma	Phase 1/Phase 2	Completed	2014-06	2016-05 (actual)
NCT01262235	A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients	Phase 1/Phase 2	Completed	2010-12	2015-07 (actual)
NCT02631096	Study of ARB-001467 in Subjects With Chronic HBV Infection Receiving Nucleos(t)Ide Analogue Therapy	Phase 2	Completed	2015-12	May 18, 2018 (actual)
NCT02041715	Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study for Intravenous (IV) TKM-100802	Phase 1	Terminated	2014-01	2015-07 (actual)
NCT01518881	Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study of Intravenous (IV) TKM-100201 Infusion	Phase 1	Terminated	2012-01	2012-07 (actual)
NCT00927459	Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Liposomal siRNA in Subjects With High Cholesterol	Phase 1	Terminated	2009-06	2009-12 (actual)